OBJECTIVES: Children are more vulnerable to ADRs, and this susceptibility is compounded due to hospitalization. There is a lack of local data regarding the potential risk of ADRs in hospitalized pediatric patients. Therefore, this study is designed to identify the frequent nature, severity of adverse drug reactions, drugs implicated and factors influencing ADRs. METHODS: Intensive monitoring study of ADRs was done in hospitalized pediatric patients of King Abdulaziz University Hospital, Jeddah from January to December 2011, with an analogous retrospective study for the preceding year to determine incidence rate, demographic aspects, causality appraisal, polypharmacy, body organs/systems involved and drugs implicated in ADR. Comparison of the two data was done to determine the impact of pharmacovigilance. RESULTS: Incidence rate of ADRs in retrospective study was (4.50%) and (8.2%) in prospective study. ADR was more in patients who received 5-6 drugs, which was (15.5%) in retrospective study and (22.1%) in prospective study. Regarding age, it was the highest in patients of 0-1 year of age which was (40.7%) in retrospective study and (38.8%) in prospective study. Anti-infective agents were the most frequently involved in ADR (40.8%) in prospective study and (48.2%) and retrospective study. This study also demonstrated that, there was high susceptibility of the skin to the ADR which was (37%) in retrospective study and (42.9%) in prospective study. None of the ADRs proved to be fatal. CONCLUSION: Well premeditated intensive monitoring approach in pharmacovigilance amplifies the ADR detection, which can persuade healthcare providers into more drug safety.
OBJECTIVES:Children are more vulnerable to ADRs, and this susceptibility is compounded due to hospitalization. There is a lack of local data regarding the potential risk of ADRs in hospitalized pediatric patients. Therefore, this study is designed to identify the frequent nature, severity of adverse drug reactions, drugs implicated and factors influencing ADRs. METHODS: Intensive monitoring study of ADRs was done in hospitalized pediatric patients of King Abdulaziz University Hospital, Jeddah from January to December 2011, with an analogous retrospective study for the preceding year to determine incidence rate, demographic aspects, causality appraisal, polypharmacy, body organs/systems involved and drugs implicated in ADR. Comparison of the two data was done to determine the impact of pharmacovigilance. RESULTS: Incidence rate of ADRs in retrospective study was (4.50%) and (8.2%) in prospective study. ADR was more in patients who received 5-6 drugs, which was (15.5%) in retrospective study and (22.1%) in prospective study. Regarding age, it was the highest in patients of 0-1 year of age which was (40.7%) in retrospective study and (38.8%) in prospective study. Anti-infective agents were the most frequently involved in ADR (40.8%) in prospective study and (48.2%) and retrospective study. This study also demonstrated that, there was high susceptibility of the skin to the ADR which was (37%) in retrospective study and (42.9%) in prospective study. None of the ADRs proved to be fatal. CONCLUSION: Well premeditated intensive monitoring approach in pharmacovigilance amplifies the ADR detection, which can persuade healthcare providers into more drug safety.
Entities:
Keywords:
ADR monitoring; Adverse drug reactions; Hospitalized patients; Pharmacovigilance
Authors: Bc Carleton; Rl Poole; Ma Smith; Js Leeder; R Ghannadan; Cjd Ross; Ms Phillips; Mr Hayden Journal: Pharmacoepidemiol Drug Saf Date: 2009-08 Impact factor: 2.890
Authors: Abdulrazaq S Al-Jazairi; Amal A Al-Agil; Yousif A Asiri; Tariq A Al-Kholi; Nathem S Akhras; Bashar K Horanieh Journal: Saudi Med J Date: 2008-02 Impact factor: 1.484
Authors: Rebecca Mary Diane Smyth; Elizabeth Gargon; Jamie Kirkham; Lynne Cresswell; Su Golder; Rosalind Smyth; Paula Williamson Journal: PLoS One Date: 2012-03-05 Impact factor: 3.240
Authors: J Kurian; J Mathew; K Sowjanya; K R K Chaitanya; M Ramesh; J Sebastian; D Narayanappa Journal: Indian J Pediatr Date: 2016-02-26 Impact factor: 1.967
Authors: Sheila Feitosa Ramos; Fernando de Castro Araújo-Neto; Giulyane Targino Aires-Moreno; Dyego Carlos Souza Anacleto de Araújo; Elisângela da Costa Lima; Divaldo Pereira de Lyra Journal: Int J Clin Pharm Date: 2021-03-03
Authors: Kazeem A Oshikoya; Gerold T Wharton; Debbie Avant; Sara L Van Driest; Norman E Fenn; Allison Lardieri; Edwin Doe; Beena G Sood; Carol Taketomo; Phuong Lieu; Lilly Yen; Ann W McMahon Journal: Paediatr Drugs Date: 2019-02 Impact factor: 3.022
Authors: Thamir M Alshammari; Khaled K Alamri; Yazeed A Ghawa; Noura F Alohali; Shaza A Abualkol; Hisham S Aljadhey Journal: Int J Clin Pharm Date: 2015-07-28